menu
    • menu
    [{"orgOrder":0,"company":"Prokaryotics","sponsor":"Prokaryotics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Antibiotic","year":"2025","type":"Licensing Agreement","leadProduct":"Spr 741","moa":"Bacterial outer membrane protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Prokaryotics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prokaryotics \/ Prokaryotics","highestDevelopmentStatusID":"6","companyTruncated":"Prokaryotics \/ Prokaryotics"},{"orgOrder":0,"company":"Prokaryotics","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2026","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Prokaryotics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Prokaryotics \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"2","companyTruncated":"Prokaryotics \/ Basilea Pharmaceutica"}]

    Find Clinical Drug Pipeline Developments & Deals by Prokaryotics

    Menu

    Prokaryotics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prokaryotics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Prokaryotics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : $48.5 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Basilea Collaborates with US Biotech on Antifungal Development

                            Details : The collaboration aims to address invasive infections caused by strains of Candida through an undisclosed miscellaneous product.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 07, 2026

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Basilea Pharmaceutica

                            Deal Size : $48.5 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prokaryotics

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Prokaryotics

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spr 741

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Northern Antibiotics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Prokaryotics Announces Licensing Agreement with Northern Antibiotics

                            Details : Prokaryotics gains worldwide rights to develop, manufacture and commercialize the Gram-negative antibiotic potentiator NAB741 (previously known as SPR741).

                            Product Name : NAB741

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            June 26, 2025

                            Lead Product(s) : Spr 741

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Northern Antibiotics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.